Study of an investigational pill for vitiligo in Chinese adults
This study tests an investigational pill called povorcitinib phosphate to see if it can help repigment skin in adults with nonsegmental vitiligo. It is a phase 3 trial in China, and participants will stop other vitiligo treatments during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have nonsegmental vitiligo (the common type affecting both sides of the body).
- Your vitiligo covers at least 5% of your body surface area, including at least 0.5% on your face.
- You agree to stop all current vitiligo treatments for the duration of the study.
- You are willing to use effective birth control (if you are of childbearing age) and follow study procedures, including skin photography.
- You do not have certain other skin conditions, serious medical issues, or infections that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called zasocitinib to see if it can help repigment skin in adults with nonsegmental vitiligo. It may be an option for people whose vitiligo covers a moderate amount of their body and who have not had certain recent treatments.
This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
This trial tests two forms of a drug (SHR0302) for non-segmental vitiligo. One is a pill, the other a gel. The goal is to see if they can repigment the skin with fewer side effects.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
Hear when a new NonSegmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.